Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

✍ Scribed by Robert R Henry; A Michael Lincoff; Sunder Mudaliar; Michael Rabbia; Cathy Chognot; Matthias Herz

• Book ID: 117304863
• Publisher: The Lancet
• Year: 2009
• Tongue: English
• Weight: 239 KB
• Volume: 374
• Category: Article
• ISSN: 0140-6736
• DOI: 10.1016/s0140-6736(09)60870-9